Literature DB >> 23261011

Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder.

Alessandra Alciati1, Piercarlo Sarzi-Puttini, Alberto Batticciotto, Riccardo Torta, Felice Gesuele, Fabiola Atzeni, Jules Angst.   

Abstract

OBJECTIVES: To test the hypothesis that the premorbid overactivity previously described in subjects with fibromyalgia is a core feature of the manic/hypomanic symptoms characterising bipolar spectrum disorders.
METHODS: 110 consecutive patients with fibromyalgia were assessed for bipolar spectrum disorders using both categorical and dimensional approaches. The first was based on a version of the DSM-IV SCID-CV interview, modified to improve the detection of bipolar spectrum disorders, the second on the hypomania symptom checklist HCL-32, which adopts a dimensional perspective of the manic/hypomanic component of mood by including sub-syndromal hypomania.
RESULTS: Both DSM-IV and Zurich criteria diagnosed high rates of bipolar spectrum disorder in patients with fibromyalgia (70% and 86.3%, respectively). Individuals with a major bipolar spectrum disorder (bipolar II disorder) and with a minor bipolar spectrum disorder (subthreshold depression and hypomania) did not differ in their demographic and clinical aspects. Hypomanic symptom counts on the HCL-32 confirmed high estimates of the bipolar spectrum, with 79% of subjects with fibromyalgia scoring 14 (threshold for hypomania) or above.
CONCLUSIONS: Overactivity reported in previous studies may be considered a core feature of hypomanic symptoms or syndromes comorbid with bipolar spectrum disorders. Major and minor bipolar spectrum disorders are not associated with differences in demographic or clinical characteristics, suggesting that fibromyalgia rather than being related specifically to depression is related to bipolar spectrum disorders and in particular to the hypomania/overactivity component.

Entities:  

Mesh:

Year:  2012        PMID: 23261011

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Development of a Novel Neuro-immune and Opioid-Associated Fingerprint with a Cross-Validated Ability to Identify and Authenticate Unknown Patients with Major Depression: Far Beyond Differentiation, Discrimination, and Classification.

Authors:  Hussein Kadhem Al-Hakeim; Suhaer Zeki Al-Fadhel; Arafat Hussein Al-Dujaili; Andre Carvalho; Sira Sriswasdi; Michael Maes
Journal:  Mol Neurobiol       Date:  2019-05-23       Impact factor: 5.590

Review 2.  False dogmas in mood disorders research: Towards a nomothetic network approach.

Authors:  Michael Hj Maes; Drozdstoy Stoyanov
Journal:  World J Psychiatry       Date:  2022-05-19

3.  Manifestation of Borderline Personality Symptomatology in Chronic Pain Patients Under Stress: An Understated and Exacerbated Consequence of the COVID-19 Crisis.

Authors:  Hannah Shapiro; Ronald J Kulich; Michael E Schatman
Journal:  J Pain Res       Date:  2020-06-15       Impact factor: 3.133

Review 4.  Psychological impact of fibromyalgia: current perspectives.

Authors:  Carmen M Galvez-Sánchez; Stefan Duschek; Gustavo A Reyes Del Paso
Journal:  Psychol Res Behav Manag       Date:  2019-02-13

5.  The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome.

Authors:  Alessandra Alciati; Fabiola Atzeni; Daniela Caldirola; Giampaolo Perna; Piercarlo Sarzi-Puttini
Journal:  J Clin Med       Date:  2020-11-10       Impact factor: 4.241

6.  The Use of Antidepressants in the Long-Term Treatment Should not Improve the Impact of Fibromyalgia on Quality of Life.

Authors:  Mg Carta; V Ruggiero; F Sancassiani; F Cutrano; Ar Manca; M Peri; A Fais; E Cacace
Journal:  Clin Pract Epidemiol Ment Health       Date:  2013-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.